Latest Sunshine Biopharma (SBFM) Headlines
Jang Attributes Peaceful Council Elections to Security Arrangements
by Seriki Adinoyi - All Africa Global Media - Wed Feb 26, 1:34AM CST
Governor Jonah Jang of Plateau State has attributed the peaceful conduct of the local government area elections in the state to the adequate security measures put in place for the exercise.
Sunshine Biopharma Begins Construction of Mouse Xenograft Models for Pancreatic Cancer to Advance Adva-27a as a Treatment for This Deadly Form of Cancer
Marketwire - Fri Feb 14, 7:00AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. The work is being conducted in collaboration with Sunshine Biopharma's parent company, Advanomics Corporation, the co-recipient of $1.45 million in research grants in Canada. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1.
Sunshine Biopharma Continues Its Efforts to Re-Domicile in Canada for Business Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate
Marketwire - Tue Feb 04, 7:04AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of proprietary drugs for the treatment of various forms of cancer, today announced that it is continuing its efforts to re-domiciling the Company in Canada in order to capitalize on management's belief that by doing so, the Company will generate additional business expansion opportunities and gain access to financing programs available to Canadian corporations. On January 31, 2014, the Company filed an S-4 Registration Statement wherein it is attempting to re-domicile to Canada from Colorado.
Sunshine Biopharma Targets Pancreatic Cancer as Second Indication for Clinical Trials of Adva-27a Compound
Marketwire Canada - Tue Jan 21, 7:08AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is now targeting pancreatic cancer as a second indication for Adva-27a, the Company's flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.
Sunshine Biopharma to Re-Domicile in Canada for Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate
Marketwire - Mon Dec 02, 7:01AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is re-domiciling the Company in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations. To this end, The Company filed a Schedule 14-C Information Statement on September 16, 2013 and an S-4 Registration Statement on October 23, 2013.
Uterine Cancer Drug Pipeline Report - H2 2013 Review
M2 - Thu Nov 07, 9:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/nz8d7g/uterine_cancer) has announced the addition of the "Uterine Cancer - Pipeline Review, H2 2013" report to their offering. 'Uterine Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer. Scope - A snapshot of the global therapeutic scenario for Uterine Cancer. - A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Uterine Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Azaya Therapeutics, Inc. - EndoCeutics, Inc. - Sunshine Biopharma, Inc. For more information visit http://www.researchandmarkets.com/research/nz...ine_cancer
Galectin Shares Rise on IND Filing, is Sunshine Biopharma Next in Line?
ACCESSWIRE - Wed Sep 18, 7:21AM CDT
Drug development is a business that can be a minefield; littered with pieces of failed companies that couldn't manage expenses and compounds that failed to meet expectations. The beauty of biotechnology, though, is a level playing field in which companies can grow robust valuations based upon target indications and assets, even at early stages of development. With initiatives around the world to expedite the regulatory pathway and major pharmaceutical companies hungry for acquisitions, there probably isn't a better time to be looking at some well-positioned up-and-comers in the space.
OTC Daily Alert Stock Watch - Sunshine Biopharma Inc., (OTCQB: SBFM)
WorldStockWire - Wed Sep 11, 10:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Sunshine Biopharma Parent Company Acquires Garmen Laboratories, a Certified GMP Manufacturing Lab
Marketwire - Mon Aug 26, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that its parent company, Advanomics Corporation, has signed a binding agreement to acquire Garmen Laboratories (Laboratoires Garmen Inc.), a Good Manufacturing Practices (GMP) laboratory with 45 employees providing complete pharmaceutical manufacturing and testing services to a broad range of industrial, institutional and governmental agencies. A profitable company, Garmen Laboratories is headquartered in a 50,000-square-foot, state-of-the-art facility in Montreal, Canada. With nearly 35 years of industry experience, Garmen delivers an array of solutions that can help detect, identify and quantify trace-level chemical components in the nutraceutical, food and pharmaceutical industries.
Sunshine Biopharma Parent Company Receives $510,000 Research Grant for Adva-27a Cancer Drug Candidate, Brings Total to $1.45 Million
Marketwire - Mon Aug 12, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its parent company, Advanomics Corporation, has been awarded a second research grant, this time from Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a, the Company's flagship anticancer drug candidate in development for multidrug resistant cancers. The grant, in the amount of $510,000, was awarded to Advanomics Corporation in collaboration with Ecole Polytechnique.
Sunshine Biopharma Parent Company Awarded Research Grant of $940,000 to Advance Adva-27a Cancer Drug Candidate
Marketwire - Tue Jul 16, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM) is pleased to announce that its parent company, Advanomics Corporation, has been awarded a research grant from the prestigious agencies Natural Sciences and Engineering Research Council of Canada ("NSERC") and NanoQuebec to advance the development of Adva-27a, the Company's flagship oncology compound targeted for multidrug resistant cancers. The grant, in the amount of $940,000, was awarded to Advanomics Corporation in collaboration with Ecole Polytechnique.
Sunshine Biopharma's Anticancer Drug Candidate, Adva-27a, Is Unaffected by the Recent Supreme Court Ruling on Patentability of Human Genes
Marketwire - Wed Jun 19, 7:00AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that its operations are unaffected by the recent Supreme Court ruling on patentability of Human Genes. Sunshine Biopharma's anticancer drug development program is not dependent on and does not utilize human genes. Sunshine Biopharma had previously reported that Adva-27a is capable of effectively killing aggressive or multidrug resistant cancer cells including Breast Cancer cells (MCF-7/MDR), Small-Cell Lung Cancer cells (H69AR), Uterine Sarcoma cells (MES-SA/Dx5), and Pancreatic Cancer cells (Panc-1).
Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells
Marketwire - Tue Jun 04, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a new IND-Enabling study in which Adva-27a, the Company's flagship oncology drug candidate for breast cancer was found to be effective at killing Pancreatic Cancer Cells in vitro. The study was carried out in the well-established very aggressive Pancreatic Cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of less than 4 micromolar, a pharmacologically very favorable drug concentration. Sunshine Biopharma had previously reported that Adva-27a is capable of effectively killing other aggressive or multidrug resistant cancer cells including Breast Cancer cells (MCF-7/MDR), Small-Cell Lung Cancer cells (H69AR), and Uterine Sarcoma cells (MES-SA/Dx5).
Jang Attributes Peaceful Council Elections to Security Arrangements
by Seriki Adinoyi - All Africa Global Media - Wed Feb 26, 1:34AM CST
Governor Jonah Jang of Plateau State has attributed the peaceful conduct of the local government area elections in the state to the adequate security measures put in place for the exercise.
Sunshine Biopharma Begins Construction of Mouse Xenograft Models for Pancreatic Cancer to Advance Adva-27a as a Treatment for This Deadly Form of Cancer
Marketwire - Fri Feb 14, 7:00AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. The work is being conducted in collaboration with Sunshine Biopharma's parent company, Advanomics Corporation, the co-recipient of $1.45 million in research grants in Canada. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1.
Sunshine Biopharma Continues Its Efforts to Re-Domicile in Canada for Business Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate
Marketwire - Tue Feb 04, 7:04AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of proprietary drugs for the treatment of various forms of cancer, today announced that it is continuing its efforts to re-domiciling the Company in Canada in order to capitalize on management's belief that by doing so, the Company will generate additional business expansion opportunities and gain access to financing programs available to Canadian corporations. On January 31, 2014, the Company filed an S-4 Registration Statement wherein it is attempting to re-domicile to Canada from Colorado.
Sunshine Biopharma Targets Pancreatic Cancer as Second Indication for Clinical Trials of Adva-27a Compound
Marketwire Canada - Tue Jan 21, 7:08AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is now targeting pancreatic cancer as a second indication for Adva-27a, the Company's flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.
Sunshine Biopharma to Re-Domicile in Canada for Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate
Marketwire - Mon Dec 02, 7:01AM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is re-domiciling the Company in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations. To this end, The Company filed a Schedule 14-C Information Statement on September 16, 2013 and an S-4 Registration Statement on October 23, 2013.
Uterine Cancer Drug Pipeline Report - H2 2013 Review
M2 - Thu Nov 07, 9:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/nz8d7g/uterine_cancer) has announced the addition of the "Uterine Cancer - Pipeline Review, H2 2013" report to their offering. 'Uterine Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer. Scope - A snapshot of the global therapeutic scenario for Uterine Cancer. - A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Uterine Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Azaya Therapeutics, Inc. - EndoCeutics, Inc. - Sunshine Biopharma, Inc. For more information visit http://www.researchandmarkets.com/research/nz...ine_cancer
Galectin Shares Rise on IND Filing, is Sunshine Biopharma Next in Line?
ACCESSWIRE - Wed Sep 18, 7:21AM CDT
Drug development is a business that can be a minefield; littered with pieces of failed companies that couldn't manage expenses and compounds that failed to meet expectations. The beauty of biotechnology, though, is a level playing field in which companies can grow robust valuations based upon target indications and assets, even at early stages of development. With initiatives around the world to expedite the regulatory pathway and major pharmaceutical companies hungry for acquisitions, there probably isn't a better time to be looking at some well-positioned up-and-comers in the space.
OTC Daily Alert Stock Watch - Sunshine Biopharma Inc., (OTCQB: SBFM)
WorldStockWire - Wed Sep 11, 10:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Sunshine Biopharma Parent Company Acquires Garmen Laboratories, a Certified GMP Manufacturing Lab
Marketwire - Mon Aug 26, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that its parent company, Advanomics Corporation, has signed a binding agreement to acquire Garmen Laboratories (Laboratoires Garmen Inc.), a Good Manufacturing Practices (GMP) laboratory with 45 employees providing complete pharmaceutical manufacturing and testing services to a broad range of industrial, institutional and governmental agencies. A profitable company, Garmen Laboratories is headquartered in a 50,000-square-foot, state-of-the-art facility in Montreal, Canada. With nearly 35 years of industry experience, Garmen delivers an array of solutions that can help detect, identify and quantify trace-level chemical components in the nutraceutical, food and pharmaceutical industries.
Sunshine Biopharma Parent Company Receives $510,000 Research Grant for Adva-27a Cancer Drug Candidate, Brings Total to $1.45 Million
Marketwire - Mon Aug 12, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its parent company, Advanomics Corporation, has been awarded a second research grant, this time from Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a, the Company's flagship anticancer drug candidate in development for multidrug resistant cancers. The grant, in the amount of $510,000, was awarded to Advanomics Corporation in collaboration with Ecole Polytechnique.
Sunshine Biopharma Parent Company Awarded Research Grant of $940,000 to Advance Adva-27a Cancer Drug Candidate
Marketwire - Tue Jul 16, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM) is pleased to announce that its parent company, Advanomics Corporation, has been awarded a research grant from the prestigious agencies Natural Sciences and Engineering Research Council of Canada ("NSERC") and NanoQuebec to advance the development of Adva-27a, the Company's flagship oncology compound targeted for multidrug resistant cancers. The grant, in the amount of $940,000, was awarded to Advanomics Corporation in collaboration with Ecole Polytechnique.
Sunshine Biopharma's Anticancer Drug Candidate, Adva-27a, Is Unaffected by the Recent Supreme Court Ruling on Patentability of Human Genes
Marketwire - Wed Jun 19, 7:00AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that its operations are unaffected by the recent Supreme Court ruling on patentability of Human Genes. Sunshine Biopharma's anticancer drug development program is not dependent on and does not utilize human genes. Sunshine Biopharma had previously reported that Adva-27a is capable of effectively killing aggressive or multidrug resistant cancer cells including Breast Cancer cells (MCF-7/MDR), Small-Cell Lung Cancer cells (H69AR), Uterine Sarcoma cells (MES-SA/Dx5), and Pancreatic Cancer cells (Panc-1).
Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells
Marketwire - Tue Jun 04, 7:01AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a new IND-Enabling study in which Adva-27a, the Company's flagship oncology drug candidate for breast cancer was found to be effective at killing Pancreatic Cancer Cells in vitro. The study was carried out in the well-established very aggressive Pancreatic Cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of less than 4 micromolar, a pharmacologically very favorable drug concentration. Sunshine Biopharma had previously reported that Adva-27a is capable of effectively killing other aggressive or multidrug resistant cancer cells including Breast Cancer cells (MCF-7/MDR), Small-Cell Lung Cancer cells (H69AR), and Uterine Sarcoma cells (MES-SA/Dx5).
